Annual results, but make it biotech
NFL Biosciences wrapped up its 2025 annual results and, in classic biotech fashion, paired the numbers with a progress update on its smoking-cessation pipeline. The big takeaway for investors? It’s still very much a development story, not a revenue machine — but it does have enough cash on hand to keep the lights on for a while.
The runway question, answered
The company says it finished the year with €3.9 million in cash, which it expects to fund operations until the third quarter of 2027. That matters because for small biopharma names, cash runway is basically the difference between “we have time to hit catalysts” and “please send dilutive financing, immediately.”
Two shots on goal
NFL is pursuing a two-pronged strategy:
- NFL-101 for targeted populations
- NFL-102 for the broader market
That’s the company’s way of trying to cover both the niche and the mass-market side of smoking cessation. If one lane is a better clinical fit and the other has bigger commercial upside, the idea is to keep both doors open instead of betting the farm on a single asset.
Why you should care
For investors, this update doesn’t scream blockbuster tomorrow. But it does tell you the company has a longer fuse than many early-stage biotechs, and that gives it room to keep pushing clinical work without immediately hitting the fundraising wall. Big picture: in biotech, cash is oxygen — and NFL Biosciences just said it has some left in the tank.